Skip to main content
SpringerLink
Log in

Screening for Pancreatic Cancer: Who to Screen and How to Follow-Up?

  • Chapter
  • First Online:
Current and Emerging Therapies in Pancreatic Cancer

  • 991 Accesses

Abstract

Early detection remains an important opportunity to improve overall survival from pancreatic cancer but is challenging in the absence of an early disease biomarker. Therefore, screening patients at increased risk for pancreatic cancer is currently the favored strategy. This approach involves careful assessment of a patient’s family history and genetic profile as well as other nongenetic risk factors. Screening is typically offered to those with an exceptionally high cumulative risk for developing pancreatic cancer. There are several remaining knowledge gaps for which additional evidence to demonstrate effectiveness and guide clinical decisions is needed. In this chapter, we review the data supporting the role of screening for pancreatic cancer and discuss practical considerations for implementing this into clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CAPS:

Cancer of the Pancreas Screening Consortium

DM:

Diabetes mellitus

EUS:

Endoscopic ultrasound

FDR:

First-degree relative

FNA:

Fine needle aspiration

FPC:

Familial pancreatic cancer

PDAC:

Pancreatic ductal adenocarcinoma

SDR:

Second-degree relative

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  PubMed  Google Scholar 

  2. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.

    Article  CAS  PubMed  Google Scholar 

  3. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88–95.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49.

    Article  CAS  PubMed  Google Scholar 

  5. Canto MI, Harinck F, Hruban RH, et al. International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.

    Article  PubMed  Google Scholar 

  6. Hart PA, Chari ST. Diabetes mellitus and pancreatic cancer: why the association matters? Pancreas. 2013;42:1207–9.

    Article  PubMed  Google Scholar 

  7. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013;42:198–201.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101.

    Article  CAS  PubMed  Google Scholar 

  9. Sah RP, Nagpal SJ, Mukhopadhyay D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10:423–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504–11.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hart PA, Baichoo E, Bi Y, et al. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015;15:162–6.

    Article  CAS  PubMed  Google Scholar 

  12. Hart PA, Kamada P, Rabe KG, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011;40:768–72.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–8.

    Article  CAS  PubMed  Google Scholar 

  14. Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102:119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148:556–64.

    Article  CAS  PubMed  Google Scholar 

  16. Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17:569–77.

    Article  CAS  PubMed  Google Scholar 

  17. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62. quiz 263

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of genetic counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70–87.

    Article  PubMed  Google Scholar 

  19. Bhalla A, Saif MW. PARP-inhibitors in BRCA-associated pancreatic cancer. JOP. 2014;15:340–3.

    PubMed  Google Scholar 

  20. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007;25:1417–22.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pelaez-Luna M, Takahashi N, Fletcher JG, et al. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007;102:2157–63.

    Article  PubMed  Google Scholar 

  23. Hart PA, Bellin M, Andersen DK. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1:226–37.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gangi S, Fletcher JG, Nathan MA, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004;182:897–903.

    Article  PubMed  Google Scholar 

  25. DeWitt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 2004;141:753–63.

    Article  PubMed  Google Scholar 

  26. Krishna S. Diagnostic performance of endoscopic ultrasound for detection of pancreatic malignancy following an indeterminate multidetector CT scan: a systemic review and meta-analysis. Surg Endosc. 2016; doi:10.1007/s00464-017-5516-y.

  27. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796–804. quiz e14-5

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946–54.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Lee KS, Sekhar A, Rofsky NM, et al. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 2010;105:2079–84.

    Article  PubMed  Google Scholar 

  30. Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008;191:802–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Moris M, Bridges MD, Pooley RA, et al. Association between advances in high-resolution cross-section imaging technologies and increase in prevalence of pancreatic cysts from 2005 to 2014. Clin Gastroenterol Hepatol. 2016;14:585–593 e3.

    Article  PubMed  Google Scholar 

  32. Konings IC, Sidharta GN, Harinck F, et al. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psychooncology. 2016;25:971–8.

    Article  PubMed  Google Scholar 

  33. Committee ASoP, Early DS, Acosta RD, et al. Adverse events associated with EUS and EUS with FNA. Gastrointest Endosc. 2013;77:839–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, 410 West Tenth Avenue, Columbus, OH, 43210, USA

    Phil A. Hart M.D. & Peter P. Stanich M.D.

  2. Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Heather Hampel M.S., C.G.C.

Authors
  1. Phil A. Hart M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter P. Stanich M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heather Hampel M.S., C.G.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Phil A. Hart M.D. .

Editor information

Editors and Affiliations

  1. Mayo Clinic Cancer Center, Scottsdale, Arizona, USA

    Tanios Bekaii-Saab

  2. Winship Cancer Institute, Emory University, Atlanta, Georgia, USA

    Bassel El-Rayes

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Hart, P.A., Stanich, P.P., Hampel, H. (2018). Screening for Pancreatic Cancer: Who to Screen and How to Follow-Up?. In: Bekaii-Saab, T., El-Rayes, B. (eds) Current and Emerging Therapies in Pancreatic Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-58256-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-58256-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-58255-9

  • Online ISBN: 978-3-319-58256-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation